Home/Rare Diseases/Gastrointestinal Stromal Tumor

Rare Cancers

Gastrointestinal Stromal Tumor

Also called GIST, GI stromal tumor, KIT positive tumor, imatinib tumor

Gastrointestinal stromal tumors (GISTs) originate from the interstitial cells of Cajal (ICC) or their precursors, cells that serve as pacemakers for gut motility. GISTs can arise anywhere in the GI tract but are most common in the stomach (60%) and small intestine (30%).

...active trials

Live from ClinicalTrials.gov

View trials below

About trials for Gastrointestinal Stromal Tumor

Mutational testing of your GIST is essential, as specific KIT or PDGFRA mutations predict response to different targeted therapies. Clinical trials are evaluating next-generation TKIs, combination strategies, and novel targets for TKI-resistant disease.

Try Match Me →

About Gastrointestinal Stromal Tumor

Gastrointestinal stromal tumors (GISTs) originate from the interstitial cells of Cajal (ICC) or their precursors, cells that serve as pacemakers for gut motility. GISTs can arise anywhere in the GI tract but are most common in the stomach (60%) and small intestine (30%). They range from small, incidentally discovered tumors to large, aggressive malignancies. The discovery that approximately 85% of GISTs harbor activating mutations in the KIT proto-oncogene (and another 5-10% in PDGFRA) transformed treatment. Imatinib mesylate, a selective tyrosine kinase inhibitor targeting KIT and PDGFRA, dramatically improved outcomes for advanced GIST and established the paradigm for molecularly targeted cancer therapy. Surgical resection remains the primary treatment for localized GIST, with adjuvant imatinib recommended for high-risk tumors. For advanced disease, sequential TKI therapy (imatinib, sunitinib, regorafenib, ripretinib) and mutation-specific agents (avapritinib for PDGFRA D842V) are available.

Common Symptoms

  • Abdominal pain or discomfort
  • A feeling of fullness after eating small amounts
  • Nausea and vomiting
  • Blood in stool or vomit (GI bleeding)
  • Fatigue from chronic blood loss anemia
  • A palpable abdominal mass (in larger tumors)

Who It Affects

Most commonly diagnosed in adults ages 50-70, with equal distribution between men and women. Can occur at any age, including rarely in children and young adults (pediatric GIST has distinct biology). No clear racial predisposition. Familial GIST syndrome and Carney-Stratakis syndrome are rare hereditary forms. SDH-deficient GISTs are a distinct subtype affecting younger patients.

Getting Involved in Clinical Trials

Mutational testing of your GIST is essential, as specific KIT or PDGFRA mutations predict response to different targeted therapies. Clinical trials are evaluating next-generation TKIs, combination strategies, and novel targets for TKI-resistant disease. The Life Raft Group and GIST Support International provide excellent trial-finding resources. For KIT-mutant GIST resistant to multiple TKIs, trials of newer agents may offer benefit. PDGFRA D842V GISTs, previously resistant to imatinib, now respond to avapritinib. SDH-deficient GISTs (wild-type for KIT/PDGFRA) require specialized evaluation. Seek care at a sarcoma center with GIST expertise for optimal management.

Trusted Sources

Active Clinical Trials for Gastrointestinal Stromal Tumor

Finding trials for Gastrointestinal Stromal Tumor...

Related Rare Cancers Conditions

Rare Cancers

NTRK Fusion Cancer

NTRK fusion cancers are a group of rare tumors driven by gene fusions involving 1 of 3 NTRK genes (NTRK1, NTRK2, or NTRK...

Rare Cancers

Cholangiocarcinoma

Cholangiocarcinoma is a rare and aggressive cancer that forms in the bile ducts, the thin tubes that carry digestive flu...

Rare Cancers

Mesothelioma

Mesothelioma is a rare, aggressive cancer that develops in the mesothelium, the thin layer of tissue covering most inter...